These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22155834)

  • 1. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.
    Ambrose PG; Hammel JP; Bhavnani SM; Rubino CM; Ellis-Grosse EJ; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1466-70. PubMed ID: 22155834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
    Bhavnani SM; Rubino CM; Hammel JP; Forrest A; Dartois N; Cooper CA; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1065-72. PubMed ID: 22143524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
    Rubino CM; Bhavnani SM; Forrest A; Dukart G; Dartois N; Cooper A; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Jan; 56(1):130-6. PubMed ID: 21968360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia.
    Wei C; Ni W; Cai X; Cui J
    Infect Dis (Lond); 2015; 47(12):846-51. PubMed ID: 26167850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.
    Passarell JA; Meagher AK; Liolios K; Cirincione BB; Van Wart SA; Babinchak T; Ellis-Grosse EJ; Ambrose PG
    Antimicrob Agents Chemother; 2008 Jan; 52(1):204-10. PubMed ID: 17954694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii.
    Ni WT; Liang BB; Cai Y; Liu YP; Bai N; Cui JC; Wang R
    Pak J Pharm Sci; 2014 May; 27(3):463-7. PubMed ID: 24811802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
    Bhavnani SM; Rubino CM; Ambrose PG; Babinchak TJ; Korth-Bradley JM; Drusano GL
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1207-12. PubMed ID: 20038623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
    Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D
    J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections.
    Xie J; Roberts JA; Alobaid AS; Roger C; Wang Y; Yang Q; Sun J; Dong H; Wang X; Xing J; Lipman J; Dong Y
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.
    Daly MW; Riddle DJ; Ledeboer NA; Dunne WM; Ritchie DJ
    Pharmacotherapy; 2007 Jul; 27(7):1052-7. PubMed ID: 17594211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of tigecycline against nosocomial pathogens in Pakistan: a multicenter study.
    Ahmed A; Zafar A; Mirza S
    J Pak Med Assoc; 2009 Apr; 59(4):240-2. PubMed ID: 19402288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia.
    Zhou Y; Xu P; Li H; Wang F; Yan H; Liang W; Xiang D; Zhang B; Banh HL
    Br J Clin Pharmacol; 2021 Jul; 87(7):2838-2846. PubMed ID: 33283892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
    Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
    Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.